GoldenGolden
Advanced Search
Gilead Sciences

Gilead Sciences

Gilead Sciences is a research-based biopharmaceutical company developing and commercializing medicines founded in 1987 by Michael L. Riordan.

Gilead Sciences is a research-based biopharmaceutical company developing and commercializing medicines that is headquartered in Foster City, California and was founded in 1987. The firm also has locations in La Vernne, California; Oceanside California; San Dimas, California; Miami, Florida; Santa Monica, California; Seattle, Washington; El Segundo, California; and Emeryville, California.

Gilead Sciences specializes in developing and commercializing biopharmaceuticals for HIV/AIDS, liver disease, hematology, oncology, inflammation, respiratory diseases, highly infectious diseases, and viral diseases. Gilead partnered with Kyverna to develop engineering T cell immunotherapies to target autoimmune diseases. The collaboration involves Kyverna’s synthetic Treg platform and synNotch, a synthetic gene expression system from the Kite unit of Gilead.

Gilead Sciences actively participates in community partnerships with COMPASS Initiative, Gilead Lift, Gilead HIV Age Positively, TRANScend, and HepConnect.

With the outbreak of COVID-19, Gilead Sciences began evaluating patients and testing remdesivir in 600 patients with moderate COVID-19 symptoms. They also began treatment of 400 patients with severe symptoms. Their results are expected in May.

Investments

Gilead Sciences has made 12 investments, 3 lead investments, and 4 exits. Notable investments made by Gilead Sciences include: Precision BioSciences, Galapagos, Phenex Pharmaceuticals, Allogene Therapeutics, National AIDS Memorial, Tmunity Therapeutics, AlloVir, Goldfinch Biopharma, Lyndra Therapeutics, and Glympse Bio. Gilead has licensed rights to filgotinib, developed by Galapagos, for rheumatoid arthritis and GLPG1690 for idiopathic pulmonary fibrosis, both in late-stage clinical studies.

Timeline

June 29, 2020
Gilead Sciences Inc announces it has set the price its Covid-19 drug candidate remdesivir at $390 per vial for the United States and governments of other developed countries.

Funding rounds

Products

Acquisitions

Invested in

Patents

Products

People

Name
Role
LinkedIn

A Deo

Employee

Aaron Arvey

Employee

Aaron Banner

Employee

Aaron DeAngelis

Employee

Aaron Mangum

Employee

...

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
IANS
July 1, 2021
@bsindia
This comes amid a sharp rise in cases of black fungus infections among Covid-19 patients in India and Nepal
BioSpace
July 1, 2021
BioSpace
DiNAQOR today announced that it has expanded the company's board of directors with three new cardiovascular industry and academic experts: Louis G. Lange , M.D., Ph.D.; Steven Zelenkofske , D.O., M.S.; and Silke Rickert-Sperling , M.D.
Alex Keown
June 29, 2021
BioSpace
If approved, lenacapavir would be offered to HIV patients who have been heavily treated for the disease and have multi-drug-resistant HIV.
Mark Terry
June 28, 2021
BioSpace
It was a busy week for clinical trial news. Here's a look.
Research and Markets
June 18, 2021
www.prnewswire.com:443
/PRNewswire/ -- The "Regenerative Medicine Market - Global Outlook and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The...
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.